摘要 |
The present invention relates to solid dosage formulations that include ERbeta-selective ligands that contain benzoxazole, and processes for manufacture of said formulations, more particularly to novel formulations and processes for manufacture of formulations containing the ERbeta-selective ligand, ERB-041.
|